Ofatumumab support treatment seems to delay movement free endurance (PFS) in patients with backslid constant lymphocytic leukemia (CLL), as indicated
Read MoreOfatumumab support treatment seems to delay movement free endurance (PFS) in patients with backslid constant lymphocytic leukemia (CLL), as indicated
Read More